The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Hepatitis D virus and liver transplantation: Indications and outcomes
World J Hepatol. 2021 Mar 27;13(3):291-299. doi: 10.4254/wjh.v13.i3.291.
Haris Muhammad1, Aniqa Tehreem2, Muhammad Baraa Hammami3, Peng-Sheng Ting3, Ramzan Idilman4, Ahmet Gurakar5
Author information
1Department ofInternal Medicine, Greater Baltimore Medical Center, Towson, MD 21204, United States.
2Department of Internal Medicine, Sinai Hospital Baltimore, MD 21204, United States.
3Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MA 21205, United States.
4Department of Gastroenterology, Ankara University School of Medicine, Ankara 06690, Turkey.
5Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, Baltimore, MA 21205, United States. aguraka1@jhmi.edu.
Abstract
Hepatitis D virus (HDV) is a dependent virus that relies on hepatitis B virus for its replication and transmission. Chronic hepatitis D is a severe form of viral hepatitis that can result in end stage liver disease. Currently, pegylated interferon alpha is the only approved therapy for chronic HDV infection and is associated with significant side effects. Liver transplantation (LT) is the only treatment option for patients with end-stage liver disease, hepatocellular carcinoma, or fulminant hepatitis due to coinfection with HDV. As LT for HDV and hepatitis B virus coinfection is uncommon in the United States, most data on the long-term impact of LT on HDV are from international centers. In this review, we discuss the indications and results of LT with treatment options in HDV patients.